Skip to main content

Advertisement

Figure 3 | BMC Cancer

Figure 3

From: Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells

Figure 3

Analysis of native Hsp90 complexes in PC3-MM2 and LNCaP cells by Blue Native Western blot and identification of the Hsp90 complex from human tissue. Native Hsp90 complexes were identified by Native Western blot (Figure 3A). 17-AAG, novobiocin and F-4, an early novobiocin analog, had little effect on the Hsp90β complex. Conversely, cytotoxic concentrations of KU174 resulted in potent disruption of the Hsp90β complex (Figure 3A). Dose-dependent effects on Hsp90β, Hsp90α, GRP94 and Hsc70 native complexes were determined following treatment of cells KU174 along with novobiocin and 17-AAG (Figure 3B). Hsp90β complex was also observed in human cancer tissue from two patient samples but to a lesser extent in their normal adjacent tissue (Figure 3C). Hsp60 served as a loading control showing relative equal loading across the patient samples. KU174 also exhibits activity in the androgen dependent cell line LNCaP resulting in Hsp90 complex disruption (Figure 3D).

Back to article page